Key result
Triple therapy with atorvastatin, probucol, and ezetimibe lowers LDL-C >40% and regresses xanthomas.
Why the study?
Effective long-term lipid-lowering strategies for homozygous familial hypercholesterolaemia in early childhood are limited and require evaluation.
Case Report (n=4)
Answers are grounded in this paper and cite their sources.
May support triple therapy in young xanthoma patients; leaves open need for randomized outcome trials.
In this observational case report, we share our experience of achieving >40% LDL cholesterol reduction in four Chinese homozygous familial hypercholesterolaemia children below 8 years of age with a triple combination of atorvastatin, probucol, and ezetimibe for >6 years. Within a follow-up duration of 6-13 years, this triple therapy achieved significant reduction of LDL cholesterol as well as an impressive regression of xanthomas in all paediatric cases. All the children remained free from treatment-related adverse responses and cardiovascular events throughout follow-up.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2015) conducted a case report in Homozygous familial hypercholesterolaemia (n=4). Atorvastatin, probucol, and ezetimibe triple combination was evaluated on LDL cholesterol reduction. Triple combination therapy with atorvastatin, probucol, and ezetimibe achieved >40% LDL cholesterol reduction and regression of xanthomas without cardiovascular events over 6-13 years of follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: